Lavender Sleep Onset Randomized Trial: What the Evidence Says

Quick Answer

Lavender Sleep Onset Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• This shift has been driven by increasing clinical and preclinical evidence supporting anxiolytic effects of standardizedessential oil preparations. [Nechepurenko Viktoriia (2026); evidence level 3]
• Nevertheless, interest in its cultivation has increased significantly in recent years. [Nechepurenko Viktoriia (2026); evidence level 3]
• A large body of evidence has accumulated suggesting the substantial pathogenic relevance of excitatory/inhibitory (E/I) imbalance in AD (Maestú et al. ). [Piccialli Ilaria (2026); evidence level 3]
• At the cellular level, aberrant neuronal excitability may promote the abnormal production and release of amyloid species into the interstitial fluid, as a result of increased neuronal firing and consequent high metabolic demand, induce neuronal damage, and foster neurodegeneration (Cirrito et al. ). [Piccialli Ilaria (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For lavender sleep onset randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Nechepurenko Viktoriia (2026). Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass. DOI: 10.1080/13880209.2026.2679806. PMCID: PMC13244516. PMID: 42248216. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13244516/
• Piccialli Ilaria (2026). Exploring Linalool‐Based Phytotherapy for Excitatory/Inhibitory Imbalance in Alzheimer's Disease: A Review of Lavender and Cannabis Therapeutic Effects on Sleep, Seizures, and Cognition. DOI: 10.1002/ptr.70191. PMCID: PMC13144443. PMID: 41735175. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13144443/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.